INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

Core Viewpoint - Vanda Pharmaceuticals Inc. is under investigation for potential securities fraud and unlawful business practices following the FDA's rejection of its supplemental New Drug Application for HETLIOZ® [1][3]. Group 1: FDA Decision - On January 8, 2026, Vanda announced that the FDA concluded the supplemental New Drug Application for HETLIOZ® for jet lag disorder cannot be approved in its current form [3]. - The FDA acknowledged positive efficacy from Vanda's clinical trials but determined that the data did not provide substantial evidence of effectiveness for jet lag disorder due to the inadequacy of the controlled phase advance protocols [3]. - Following the FDA's announcement, Vanda's stock price fell by $1.20 per share, or 14.05%, closing at $7.34 per share on January 8, 2026 [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Vanda's investors regarding potential securities fraud or other unlawful business practices by the company and its officers and/or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2][6]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4]. - The firm has a legacy of recovering multimillion-dollar damages awards for class members over its 85-year history [4].